Exploring Clec9a in dendritic cell-based tumor immunotherapy for molecular insights and therapeutic potentials
Abstract The pivotal role of type 1 conventional dendritic cells (cDC1s) in the field of dendritic cell (DC)-based tumor immunotherapies has been gaining increasing recognition due to their superior antigen cross-presentation abilities and essential role in modulating immune responses. This review s...
Saved in:
Main Authors: | Zubair Hussain, Yueteng Zhang, Lu Qiu, Shanshan Gou, Kangdong Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-02-01
|
Series: | npj Vaccines |
Online Access: | https://doi.org/10.1038/s41541-025-01084-2 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CLEC11A-Driven Molecular Mechanisms in Intervertebral Disc Degeneration: A Comprehensive Multi-Omics Study
by: Jiang N, et al.
Published: (2025-01-01) -
Structural insights into antibody-based immunotherapy for hepatocellular carcinoma
by: Masaud Shah, et al.
Published: (2025-01-01) -
The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook
by: Hager Mohamed, et al.
Published: (2020-01-01) -
Harnessing dendritic cells for pancreatic cancer immunotherapy: a novel promising approach
by: Hui Zeng, et al.
Published: (2025-01-01) -
Molecular Mechanisms and Therapeutic Prospects of Immunotherapy and Targeted Therapy in Primary Central Nervous System Lymphoma
by: Lin Zhong MM, et al.
Published: (2025-02-01)